In summary, CD44 is often used as a marker for CSCs, particularly in breast cancer and in head and neck cancer, because CD44-positive cells are associated with properties that are often attributed to CSCs, such as self-renewal and tumor-initiating capabilities. This evidence concerns the gene CD44 and breast cancer.